BENEFIT-RISK INTEGRATION AND REPRESENTATION
Ashby D, Future directions of benefit-risk assessment in Europe, ISPE Mid-Year Meeting, Munich 11-12 April, 2013
Shahrul Mt-Isa, Formal Benefit Risk Approaches in regulatory decision making of medicinal products, 16th Joint Swiss Symposium on Pharmaceutical Medicine, Berne, 28 November
Shahrul Mt-Isa, Emerging methods in benefit-risk assessment and decision-making for medicinal products, European statistical Forum, 19 November, Berlin 2012
Dierig Ch, Nixon R, A Case Study using the BRAT framework for Benefit Risk Assessment, Basler Biometric Section, 25 September 2012,
Van den Ham et al.- The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation, 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23-26 Aug 2012, Barcelona
Ashby D.- What role should risk benefit decision making play in the regulation of medicines, Conference on Applied Statistics, Ireland, 16-18 May 2012
Nixon R.- Benefit Risk Analysis: Experience in using the BRAT framework, PSI Annual Conference, Birmingham, 15 May 2012
Ashby D.- Benefit-Risk Integration and Representation, CHMP ORGAM, 09th June 2011
Ashby D.- Current methodological approaches to risk-benefit decision making, DIA EuroMeeting, Geneva, 28-30 March 2011
Van Staa et al.- Methods for harm-benefit modelling; 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23-26 Aug 2012, Barcelona
Ashby et al, Benefit Risk analysis of using formal BR approaches for decision making in drug regulation; President’s Invited Lecture, ISCB-33, 22 August
Hockley K.- Patient and Public Involvement in Regulatory Decision Making, Medical Research Council Phd Student Symposium, 01 May 2012
Micaleff A.- The PROTECT Consortium, CIRS Annual meeting Washington: Visualising Benefit-Risk, 16-17 June 2011